Modulation of an individual's gut microbiome to address osteoporosis and bone disease
Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.
1. A method for reducing the likelihood of developing osteoporosis in an individual human being, comprising: providing via oral administration a population of beneficial bacteria that produce butyrate, said beneficial bacteria encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid, said beneficial bacterial comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzi and Akkermansia muciniphila ; and administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being.
2. The method as set forth in claim 1 , wherein the individual is a postmenopausal woman.
3. The method as set forth in claim 1 , further comprising providing to the individual at least about 300 mg of tributyrin.
4. The method as set forth in claim 1 , further comprising reducing the number of bacteria in the individual using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.
5. The method as set forth in claim 1 , wherein said beneficial bacteria have been modified by using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system.
6. The method of claim 1 , further comprising administering to the individual at least 10 micro-mole of tomatidine.
7. The method as set forth in claim 1 , further comprising administering one of rapamycin and resveratrol to the individual.
8. A method for reducing the likelihood of developing osteoporosis bifidobacteria and Faecalibacterium prausnitzii , wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid; administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis; and administering at least one of tomatidine and rapamycin to the individual using a bioadhesive strip that has a first and second side, the second side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person's mouth, said strip including at least one polymer selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, chitin, chitosan, levan, elsinan, collagen, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.
9. A method for reducing the likelihood of developing osteoporosis bifidobacteria and Faecalibacterium prausnitzii , wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid; administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis; and reducing bacteria in the gut of the individual, wherein the bacteria reduced are selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.
10. The method of claim 9 , wherein the step of reducing the number of bacteria comprises administering an antibiotic.
11. A method for reducing the likelihood of developing osteoporosis bifidobacterial and Faecalibacterium prausnitzii , wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid; administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis; and administering between 500 mg and 1000 mg of tributyrin to the individual.
12. A method for reducing the likelihood of developing osteoporosis bifidobacteria and Faecalibacterium prausnitzii , wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid; administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis; wherein the individual is a postmenopausal woman.
13. A method for reducing the likelihood of developing osteoporosis bifidobacteria and Faecalibacterium prausnitzii , wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid; administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis; and reducing the number of bacteria in the individual using one of an antibiotic, a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system.
14. The method as set forth in claim 12 , further comprising providing to the individual at least about 300 mg of tributyrin.